retreatment with pegylated interferon alpha-2a and ribavirin in patients with chronic hepatitis c who have relapsed or not responded to a first course of pegylated interferon-based therapy
;Eric M Yoshida;Morris Sherman;Vincent G Bain;Curtis L Cooper;Marc Deschênes;Paul J Marotta;Samuel S Lee;Mel Krajden;Helga Witt-Sullivan;Robert J Bailey;Christopher Usaty;Kevork Peltekian;the Canadian Pegasys Study Group
indian journal of pharmacology2009Vol. 23pp. 180-184
212
yoshida2009canadianretreatment
Abstract
BACKGROUND: Pegylated interferon (pegIFN) and ribavirin combination therapy remains the first-line treatment for chronic hepatitis C virus (HCV) infection. In contrast to the wealth of studies in treatment-naive patients, the effectiveness of retreatment in patients who have previously failed pegIFN-based therapy is largely unreported.